Dear Shareholder:

The Road Ahead

  e are immensely proud of all we have accomplished during the past year and the past decade. The capabilities we have built in R&D and across the Company are delivering innovative products to save and improve lives. We hope our work on Meningitis conjugate vaccine, TIA / Stroke and Alzheimer's disease biomarkers and therapeutics will make a difference for the patients and families who suffer. We believe that as NmVac-4DT (serogroups A, C, Y & W135) will be introduced in several countries in 2012-2013, the lives of hundreds of thousands of adults and children eventually will be saved.

We know that NmVac-2 comprising serogroups A&C already has made an extraordinary difference in the lives of people in sub-Saharan Africa and India who have benefited from its use.  To continue and expand this record of achievement, we will remain flexible and resilient in seeking better ways to deliver accessible and affordable health care.

" Nmvac-4 DT is among the most complex biotech or biologic products ever made, it's a combination vaccine that contains 4 glycoconjugates or 4 different vaccines in one. It combines, or conjugates, the seven different polysaccharides or sugars found on the cell coats of each of seven different bacterial strains in the vaccine with a carrier protein that enhances their effect."

As we do all this, we will be guided by five principles: Our values. Science and innovation. Leadership. Sound financial decisions and belief in our noble cause improving the lives of people through medical advances and putting the patient at the center of everything we do. We thank our colleagues at JN for their innumerable contributions and for their dedication to reshaping our Company in order to make it stronger. As we look to the future, we believe that the support and hard work of our people will help us to grow, to prosper and to lead as we build the most trusted and respected health care company in the world.

Thank you so much for your continuous support, patience and encouragement.



Dr. Jeeri R Reddy

Chairman of the Board President

and Chief Executive Officer

November 17, 2011

Investors Home Page

elcome investors

This site provides current and potential investors with information that is pertinent to the investment and financial community, including share price and trade volumes. 

Assets & Stock: Nebraska Secretary of State: The assets of the corporation = $24.144 million in 2006-2007and during 2010 the assets increased to $125 million (unaudited) based on Building, Equipment, issued Patents, Sales and Vaccine stock of the corporation. 36,000 shares were on Jan 2011-2012 is $9,341 / share on private par  (12,000 shares issued).  The share selling price has been adjusted according to number shares issued under "C" corporation statue of the State of Nebraska.  Subsidiary company assets not included. 

Financial performance: JN corporation has been well funded by the private investors and through US govt. research grants and revenues generated by marketing third party products. There is limited deficiency in funds to complete the projects. However, qualified investors and venture capitalists are welcome to purchase our stock at private par. It is anticipated that our Meningitis vaccine will be in the international market in 2012 and in North American market in 2013-2014.

A commitment to Shareholders: “Jn-International Medical Corporation is committed to create significant value for its  shareholders, customers and partners through a sustainable business strategy balancing short-term and long-term growth potentials ” - Account statements are submitted to the investors electronically at every 4 months. IRS tax returns and Corporate publications can be requested by telephone or e-mail and will be mailed by FedEx. Our investors always thanking to our world-class researchers, state-of-the-art technologies and facility engineers and unrelenting focus on scientific excellence, JN is at the forefront of discovering and developing innovative ways to treat and prevent disease. 

Financial documents and investor-related materials are available for review. You may request financial statements material by contacting us by telephone or email.


At JN code of conduct reflects our corporate values. We hold ourselves to high standards of ethical behavior, We work hard to make sure that the integrity of this company remains a priority for employees, customers, and shareholders.





2011 FDA authorized JN's IND for conducting NmVac4-DTconjugate Meningitis vaccine human trials in Hanford, California


2011 Neurology scientists bags Stroke Grant Award - US Govt.


2011 TIA Stroke Intervention promise


2006-2011 Meningitis vaccine for Disease outbreaks in India & sub-Saharan



Scientific Excellence

SINCE 1998




Annual Report 2007> 

Annual Report 2008>

Annual Report 2009>



JN-International Inc. USA

JN-International Medical Corporation





2720 North 84th Street. Omaha,

Nebraska NE 68134

(402)884-3477 ; (402) 932-7931.

(402) 932-7932; Fax (402) 614-4437;